Moderna (MRNA)
NASDAQ:MRNA
Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$53.72
-$4.21(-8.86%)
At close: 4:00 PM EST
$53.72
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $59.55
Previous CloseN/A
Volume7.58M
Average Volume (3M)7.24M
Market Cap
$18.72B
Enterprise Value$18.11B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
-2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.15
Shares Outstanding396,786,250
10 Day Avg. Volume5,015,632
30 Day Avg. Volume7,239,519
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue8.14
Enterprise Value/Gross Profit-58.62
Enterprise Value/Ebitda-6.13
Forecast
1Y Price Target
$44.61Price Target Upside-16.96% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-8.66
Revenue Forecast (FY)$2.09B
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength And Low LeverageModerna's large cash balance and low leverage provide a multi‑quarter runway to fund R&D, manufacturing scale-up and commercialization while absorbing one-time charges. This liquidity supports strategic optionality and reduces near-term refinancing risk, preserving long-term operational flexibility.
Regulatory Approvals And Product Portfolio ExpansionRecent approvals and multiple filings broaden Moderna's commercial product set beyond COVID boosters, creating diversified revenue channels. Durable regulatory wins and additional approvals (combo vaccine, flu filings) strengthen market position and reduce reliance on a single product over the medium term.
Sustained Cost Discipline And Improving Operating EfficiencyMeaningful, repeatable reductions in cash costs and operating expenses indicate management is structurally lowering burn rate. If maintained, these efficiencies reduce cash consumption, lengthen runway for pipeline development, and improve the path to sustainable non‑GAAP profitability over coming quarters.
Bears Say
Sustained Negative Cash GenerationPersistent negative OCF and FCF reflect that current revenue does not yet support Moderna's cost base and R&D spend. Continued cash burn raises structural funding risk and could force reprioritization of programs or additional financing if revenues and margins do not improve.
Large Legal Settlement And Contingent LiabilitiesA substantial settlement and potential further liability materially increase long‑term cost of goods and cash outlays. This structural legal overhang reduces predictable margins on affected products and injects multi‑year uncertainty into cash planning and free cash flow forecasts.
Expected Multi‑quarter Cash Drawdown To Fund OperationsPlanned cash drawdown signals continued reliance on existing liquidity to fund pipeline and operations. If revenue growth or margins lag, this structural consumption could pressure flexibility for late‑stage trials, manufacturing investments, or force external financing under unfavorable terms.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $59.55 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $18.72B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 01, 2026. The company reported -$3.4 earnings per share for the quarter, beating the consensus estimate of -$4.446 by $1.046.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.06.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.4 in its last earnings report, beating expectations of -$4.446. Following the earnings report the stock price went down -1.241%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.61 (-16.96% Downside)
$44.61 (-16.96% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 178.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.41%
12-Months-Change
Fundamentals
Return on Equity
-36.73%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$44.61
▼(-16.96% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.73% Insiders
27.67% Mutual Funds
20.59% Other Institutional Investors
21.48% Public Companies and Individual Investors